---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-290003"
form_type: "8-K"
ticker: "CLPT"
cik: "0001285550"
company_name: "ClearPoint Neuro, Inc."
filed_at: "2025-11-20T23:59:59+00:00"
generated_at: "2026-05-16T17:54:08.016332+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ClearPoint Neuro completes acquisition of IRRAS for $5M cash + 1.325M shares

## Summary
- Acquisition closed Nov 20, 2025; IRRAS shareholders received $5M cash and 1.325M CLPT shares.
- Earnout consideration: 25% of net sales of certain IRRAS products above thresholds over three one-year periods.
- IRRAS brings IRRA flow fluid-exchange system for intracranial bleeding, 50+ active customers, and commercial team.
- ClearPoint Neuro expects expanded presence in neurocritical care and enhanced commercial scale from the deal.

## SEC filing metadata
- accession: 0001193125-25-290003
- form_type: 8-K
- ticker: CLPT
- cik: 0001285550
- company_name: ClearPoint Neuro, Inc.
- filed_at: 2025-11-20T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285550/000119312525290003/0001193125-25-290003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285550/000119312525290003/clpt-20251120.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-290003
- JSON: https://secwatch.observer/filing/0001193125-25-290003.json
- Plain text: https://secwatch.observer/filing/0001193125-25-290003.txt

## Source-grounded claims
- claim_id: 0f8c6ce8f13caed312e6ec22fae7c4f13ba2fc29
  claim: ClearPoint Neuro, Inc. completed an acquisition involving IRRAS Holdings, Inc. for $5,000,000 in cash and 1,325,000 shares of Company common stock (closed 2025-11-20).
  evidence_excerpt: the “Merger”), with the Second Merger Sub surviving the Second Merger. Merger Consideration Pursuant to the Merger Agreement, the Company delivered closing consideration of $5,000,000 in cash and 1,325,000 shares of Company common stock to IRRAS shareholders (the “Closing Shares”). Earnout Consideration As additional consideration for IRRAS’ stockholders, the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1285550/000119312525290003/0001193125-25-290003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.